GHRP-6, also catalogued as SKF-110771, is a synthetic growth hormone releasing peptide from the same generation as GHRP-2. Like GHRP-2, it is restricted from routine 503A compounding. Its distinguishing clinical characteristic is the intensity of the appetite stimulation it produces.
This guide situates GHRP-6 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is GHRP-6?
GHRP-6 is a synthetic hexapeptide that activates the growth hormone secretagogue receptor, GHS-R1a — the ghrelin receptor. It stimulates pituitary growth hormone release and is administered by subcutaneous injection.
It was among the earliest compounds of its type and is historically significant: work with GHRP-6 helped lead researchers to the discovery of ghrelin itself. The peptide was found before the natural hormone it imitates.
The appetite effect
Every ghrelin receptor agonist stimulates appetite to some degree, because ghrelin is the body's hunger signal. GHRP-6 produces this effect more intensely than the other secretagogues, and patients describe it as pronounced and difficult to ignore.
Whether that is desirable depends entirely on the clinical objective. In a genuine cachexia or wasting context, where the therapeutic goal is to increase intake, intense appetite stimulation is the mechanism working as intended. In the far more common scenario — a patient pursuing body composition improvement or fat loss — it works directly against the goal, and the compound is poorly matched to the objective.
GHRP-6 shares the selectivity limitation of its generation: it raises cortisol and prolactin alongside growth hormone, unlike the selective agents developed later.
Regulatory status
GHRP-6 is restricted from routine 503A compounding and is not an FDA-approved drug in the United States. As with GHRP-2, this is a regulatory determination governing whether the substance may be compounded, not a formality.
The regulatory ground across this category has shifted repeatedly since 2023, including removals from Category 2 in April 2026 that did not extend to the GHRPs. Because the position of individual peptides changes, current status should be confirmed rather than assumed — our peptide formulary tracks it agent by agent.
Material sold online under this name is an unregulated research chemical with no verified identity or purity.
What to tell patients
GHRP-6 appears in older internet protocols and continues to be requested by name. The useful clinical response addresses the mismatch rather than only the legality: for a patient whose aim is fat loss or body composition, a compound whose most reliable effect is intense hunger is working against them.
For the broader question of what growth hormone secretagogues can realistically deliver — and the difference between raising a biomarker and changing an outcome — our growth hormone peptides guide covers the class honestly.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering growth hormone axis biology, secretagogue selectivity, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →